SciFluor reports Phase I/II data for SF0166 in wet AMD

SciFluor Life Sciences Inc. (Cambridge, Mass.) reported top-line data from 42 evaluable patients with wet age-related macular degeneration (AMD) in a Phase I/II trial showing that SF0166 Topical Ophthalmic Solution met the primary safety endpoint with no treatment-related serious adverse events reported. Ocular adverse events were reported in the treated eyes of five patients and all events were mild or moderate in severity. SF0166 was well tolerated.

Additionally, SF0166 reduced central retinal thickness and/or subretinal fluid as measured by spectral domain optical coherence tomography in 9 patients. Among treatment-naïve patients, SF0166 also improved best corrected visual acuity (BCVA) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart by a mean of 5 letters. ...